A Phase 4 interventional study of Pegvisomant treatment and Medical History, demographics in Acromegaly, sponsored by Pfizer. Completed at 5 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-24.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
203 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
This study's enrollment of 30 is below the median of 43 across 116 interventional studies indexed under Acromegaly.
Browse Acromegaly studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient's IGF-1 levels normalize signs and symptoms of acromegaly normalize
Pegvisomant demonstrates continued safety and efficacy
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.